Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.
about
Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) ratsTriple reuptake inhibitors: the next generation of antidepressantsReview of pharmacological treatment in mood disorders and future directions for drug development.Triple uptake inhibitors: therapeutic potential in depression and beyondCurrent investigational drugs for major depressionEffect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring ratEfficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsEffects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activityTriple Reuptake Inhibitors: A Premise and PromiseDirected evolution strategies for enantiocomplementary haloalkane dehalogenases: from chemical waste to enantiopure building blocks.Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.Monoamine transporters: vulnerable and vital doorkeepers.Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs).
P2860
Q24631019-CB02B946-CBE2-4467-9EAC-312BBBDDD5ACQ24658248-CB65E6E5-CDC2-416B-89A2-B5BE10EDC070Q26853509-DB08F7DC-D386-429F-9953-37E9FD82EFBDQ28241732-B5E13D27-C8A5-4B1F-9E81-05A00C8C0AD8Q28244223-C2E08954-DED0-4AE8-BE20-9C4A85F128EFQ28251435-4AE98B42-B64F-468D-A31B-854FBE40C3C7Q28252146-C1FF8F8C-049F-4538-B6C1-10682F897DC7Q28256557-71ED5083-E78D-46DF-9CEF-19017BB7739CQ28972234-EA40F4E5-5743-4A2C-B814-E3767E15FF36Q31042124-12293DDF-A807-4594-B6F1-C3795FB5D5F1Q33999301-63A61FDE-893C-45E2-B8E2-885C0A176CECQ34251275-350992AF-A714-474D-AB81-85E682219636Q35877150-265CEC5F-4EFF-46C0-9AC2-BC6ACEFA9530Q36511165-C8F4963C-29C0-4CF6-8FD0-0AF691E398BEQ37158450-CA7F0553-09FF-49CA-8482-2AF8E394853CQ37700079-886974DD-0F1C-450E-ABA4-88F26F5AD633Q55421497-71CE1E8A-B27E-4792-BCC6-0A28DA01C83D
P2860
Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@ast
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@en
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@nl
type
label
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@ast
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@en
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@nl
prefLabel
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@ast
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@en
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@nl
P2093
P50
P1476
Pharmacological profile of the ...... uptake inhibitor, DOV 102,677.
@en
P2093
Aaron Janowsky
Anthony S Basile
Arnold Lippa
Phil Skolnick
P2888
P304
P356
10.1007/S10571-006-9012-5
P577
2006-04-25T00:00:00Z
P6179
1020035037